Clinical trials: Coronavirus (SARS-CoV)
Covid19, SARS-CoV Infection
Prognostic Value of Flow-mediated Dilation in Hospitalized COVID-19 Patients
This study will evaluate the associations between vascular parameters and clinical outcomes in patients hospitalized with COVID-19.
- Trial name
- NCT04714125
- Where
- Brazil
- Volunteers
- 250 people
- Sponsor
- University of Sao Paulo General Hospital
Coronavirus, Acute Respiratory Infection
Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease
ORCHID is a multicenter, blinded, placebo-controlled, randomized clinical trial evaluating hydroxychloroquine for the treatment of adults hospitalized with COVID-19.
- Conditions
- Coronavirus, Acute Respiratory Infection, SARS-CoV Infection
- Trial name
- ORCHID (NCT04332991)
- Testing
- Hydroxychloroquine
- Where
- 40 sites in United States
- Volunteers
- 479 people
- Sponsor
- Massachusetts General Hospital
Severe Acute Respiratory Syndrome-related Coronavirus, Renal Dialysis
Medicine-induced Cardiac Hemodialysis on COVID-19
The clinical trial studies the human pathogen of SARS-CoV-2, with a specificity in the circulating Spike 2 protein in the human system.
- Conditions
- Severe Acute Respiratory Syndrome-related Coronavirus, Renal Dialysis, Vaccines, Myocarditis Allergic
- Trial name
- NCT05711810
- Testing
- Nifedipine 30 MG, Kangzhu BPCB0A-3A, Low Mobility
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Yang I. Pachankis
SARS CoV 2 Infection
A Safety and Tolerability Study of Sotrovimab (VIR-7831) Prophylaxis Against COVID-19 in Immunocompromised Individuals
This is an open-label study examining the safety and tolerability of sotrovimab, administered in two sequential doses as prophylaxis in immunocompromised patients with impaired humoral immunity against SARS-CoV-2.
- Trial name
- NCT05210101
- Testing
- Sotrovimab
- Where
- 3 sites in United States
- Volunteers
- 93 people
- Sponsor
- Sophia Koo, M.D.
SARS-CoV Infection, Covid19
'4C' Intervention to Reduce SARS-CoV-2 (Covid-19) Transmission
Nursing homes have long faced special challenges in implementing effective infection prevention programs, including limited resources and diagnostic challenges in a frail functionally disabled long-stay population.
- Trial name
- NCT04739449
- Testing
- Coaching, Cleaning, Communication, Collaboration
- Sponsor
- University of Michigan
Covid-19, Corona Virus Infection
Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19
Introduction There are currently no treatments with demonstrated efficacy for COVID-19 infection. Epidemiological evidence points to the existence of intrinsic protection factors which make young persons and women more resistant…
- Conditions
- Covid-19, Corona Virus Infection, SARS-CoV 2
- Trial name
- OsCOVID19 (NCT04386447)
- Testing
- Oxytocin, Standard of Care
- Where
- 3 sites in France, Italy
- Sponsor
- Azienda Ospedaliero-Universitaria di Parma
Coronavirus Infections, SARS-CoV 2
Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19)
The Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV2) has been identified in Wuhan, China, which causes severe pulmonary complications and flu syndrome, which has spread rapidly to all continents.
- Conditions
- Coronavirus Infections, SARS-CoV 2, SARS (Severe Acute Respiratory Syndrome), Pulmonary Disease
- Trial name
- NCT04361461
- Testing
- Hydroxychloroquine Sulfate, Hydroxychloroquine Sulfate + Azythromycin
- Where
- Brazil
- Sponsor
- Apsen Farmaceutica S.A.
SARS CoV 2 Infection, COVID-19
Humoral and Cellular Immunity in First-cycle SARS-CoV-2 Vaccinated COVID-19 Patients
Infection by the recent Coronavirus (SARS-CoV-2) has generated at a pandemic level a new pathology, called COVID-19, characterized by "flu-like" symptoms up to severe acute respiratory failure.
- Trial name
- NCT05338736
- Testing
- LIAISON SARS-CoV-2 TrimericS IgG (DiaSorin), LIAISON SARS-CoV2-IgM (DiaSorin), Human IFN-g ELISpot PLUS (ALP) (AUROGENE)
- Where
- Italy
- Volunteers
- 45 people
- Sponsor
- University Magna Graecia
SARS-CoV Infection
VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study
To demonstrate the efficacy of VERU-111 in the treatment of SARS-Cov-2 Infection by assessing its effect on the proportion of patients who die on study (prior to Day 60).
- Trial name
- VERU-111 (NCT04842747)
- Testing
- VERU-111
- Where
- 58 sites in United States, Argentina and 4 more
- Volunteers
- 204 people
- Sponsor
- Veru Inc.
Covid19, SARS (Severe Acute Respiratory Syndrome)
A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19
In this randomized double blind Phase 3 clinical trial we will study the efficacy and safety of oral polio vaccine with and without NA-831 versus placebo.
- Conditions
- Covid19, SARS (Severe Acute Respiratory Syndrome), SARS-CoV Infection, SARS-CoV-2
- Trial name
- OPV-NA831 (NCT04540185)
- Testing
- Biological: oral polio vaccine, NA-831, Combination of oral polio vaccine and NA-831
- Where
- 10 sites in United States, New Zealand
- Volunteers
- 3,600 people, healthy volunteers welcome
- Sponsor
- Biomed Industries, Inc.
SARS CoV 2 Infection
A Study of EDP-235 in Healthy Subjects
This study is a randomized, double-blind, placebo-controlled study. It will assess the safety, tolerability, and pharmacokinetics of orally administered single and multiple doses of EDP-235 in healthy adult subjects.
- Trial name
- NCT05246878
- Testing
- EDP-235
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
COVID, SARS-CoV 2
COVID-19 Immune Repertoire Sequencing
This concerns a single-center prospective interventional cohort study. Laboratory-confirmed COVID-19 patients will be asked to donate blood at at least two different timepoints.
- Conditions
- COVID, SARS-CoV 2, Corona Virus Infection, RDT
- Trial name
- IMSEQ (NCT04368143)
- Where
- Belgium
- Volunteers
- 84 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Corona Virus Infection, SARS-CoV 2
Registry for Clinical Presentation and Management of Patients With COVID-19 in the Emergency Room
Patients with COVID-19 usually present in the ED and receive their initial medical check-up here. We will try to gather information of comorbidities and other conditions at the time of presentation of COVID-19 patients to the ED.
- Trial name
- ReCovER (NCT04351854)
- Testing
- Retrospective data collection
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- University of Cologne
Covid-19 Prevention
A Study of Ad26.COV2.S in Adults (COVID-19)
The purpose of the study is to assess the safety, reactogenicity, and immunogenicity of Ad26.COV2.S at 2 dose levels, administered intramuscularly (IM) as a single-dose or 2-dose schedule, with a single booster vaccination…
- Trial name
- NCT04436276
- Testing
- Ad26.COV2.S
- Where
- 12 sites in United States, Belgium
- Volunteers
- 1,085 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
SARS-CoV 2
Current and Past SARS-CoV-2 Infection and COVID-19 in Healthcare
The SARS-CoV-2 pandemic and resulting COVID-19 disease causes a substantial burden on healthcare systems. Little is known about how the infection spreads within healthcare.
- Trial name
- NCT04411576
- Testing
- Throat swab sample for measuring current infection with SARS-CoV-2, Blood sample for serology to measure past infection with SARS-CoV-2
- Where
- Sweden
- Volunteers
- 26,326 people
- Sponsor
- Karolinska University Hospital
Influenza and Other Novel Respiratory Viruses
Respiratory Virus Outpatient Study (FLU 002 Plus)
Following the sudden and unexpected emergence of influenza A(H1N1)pdm09 (2009 H1N1) virus, this observational study was initiated to describe participants seeking medical care in geographically diverse locations with 2009 H1N1…
- Trial name
- NCT01056354
- Where
- 68 sites in United States, Argentina and 13 more
- Volunteers
- 11,719 people
- Sponsor
- University of Minnesota
SARS-CoV Infection, Polymerase Chain Reaction
Self-Collected Saliva Samples Without Viral Transport Media for COVID-19 Testing Via RT-PCR
This is a study that will attempt to validate the process for detecting SARS-CoV-2 (COVID19) on a non-FDA-approved technology using self-collected saliva as the specimen.
- Conditions
- SARS-CoV Infection, Polymerase Chain Reaction, Laboratory Testing
- Trial name
- NCT04604145
- Testing
- SARS-CoV-2 testing on the Eppendorf Thermal Cycler PCR system using self-collected saliva as the specimen
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- David Grant U.S. Air Force Medical Center
Covid-19, Critical Illness
MIcrovascular Dysfunction in CRitically Ill cOVID-19 Patients
Microcirculatory dysfunction appears to play a key role in the development of organ failure leading to the death of patients with coronavirus disease 2019 (Covid-19).
- Conditions
- Covid-19, Critical Illness, Hemodynamics, SARS-CoV Infection
- Trial name
- MICROVID (NCT04819802)
- Testing
- Measurement of sublingual microcirculation, Plasma sampling
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Covid19, Obstetric Complication
COVID-19 Infection and Fetal-neonatal Outcomes
COVID-19, the coronavirus responsible for the pandemic that began at the end of 2019 in China, spreads through respiratory droplets and direct contact.
- Conditions
- Covid19, Obstetric Complication, SARS-CoV Infection, Preterm Birth
- Trial name
- NCT04699578
- Testing
- Covid-19 positive
- Where
- Italy
- Volunteers
- 230 people
- Sponsor
- University of Campania Luigi Vanvitelli
Covid19, SARS-CoV Infection
Immunogenicity, Efficacy and Safety of QazCovid-in® COVID-19 Vaccine
Multicenter, randomized, blind, placebo-controlled clinical study of III phases on the assessment of preventive efficiency, safety and immunogenicity QazCovid-in®-vaccine against COVID-19 in healthy adult volunteers
- Conditions
- Covid19, SARS-CoV Infection, Vaccine Adverse Reaction
- Trial name
- NCT04691908
- Testing
- QazCovid-in®-vaccine against COVID-19
- Where
- Kazakhstan
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Research Institute for Biological Safety Problems